Prescription drug prices: White House estimates USD 529 billion savings from Trump drug-price deals

White House economists estimated that President Donald Trumps drug-pricing deals could cut US prescription costs and save USD 529 billion over 10 years. The projections, obtained by The Associated Press, underpinned a central part of Trumps message before Novembers midterm elections. The policy aimed to bring some US drug prices closer to levels charged in other countries.

Representative image

Cost pressures remained a major voter concern, and the public faced added worry from higher energy prices tied to the Iran war. Trump focused on drug affordability as part of that wider debate. At a Friday rally in Florida with many seniors, Trump said, "Now you have the lowest drug prices anywhere in the world.\"

Trump drug prices plan and projected savings

The study came from administration officials working for the White House Council of Economic Advisers. It also estimated combined federal and state savings of USD 64.3 billion for Medicaid over the next decade. Those numbers relied on what Trump called a most favoured nation policy. The report modelled larger possible savings too, including USD 733 billion.

According to the most recent government figures, Americans spent USD 467 billion on prescription drugs in 2024. The White House projections suggested the policy could be significant at that scale. Trump also told the Florida crowd, \"And that alone should win us the midterms.\" The administration and the Department of Health and Human Services urged Congress to put the approach into law.

Trump drug prices deals and transparency questions

Many agreement terms remained private, because few details of the deals were made public. The Trump administration said it reached deals with 17 leading pharmaceutical companies. That limited disclosure made independent checks of the estimated savings difficult. White House officials framed the analysis as forward-looking, as more medicines entered the market under the framework.

Democratic lawmakers questioned the claimed savings and signalled more scrutiny. Senate Finance Committee Ranking Member Ron Wyden, D-Ore., and 17 Senate Democrats in April proposed a measure. It would require the administration to disclose the agreement terms. Wyden asked, \"If these deals are so great, why is the Trump administration afraid of showing them to the public?\"

Health Secretary Robert F. Kennedy Jr. said some information would be shared. Robert F. Kennedy Jr. said the team would release details that avoided proprietary information or trade secrets. Democrats still argued the new figures could raise more questions about the data. The midterm context increased the political stakes around the estimates and the details.

Trump drug prices model and what critics say

The White House analysis depended on an assumption about other countries pricing. It suggested foreign governments would pay more for prescription drugs. That shift would widen drugmakers revenue sources and maintain their ability to innovate. The White House presented this as a way to balance lower US prices with ongoing research into new treatments.

Outside estimates offered a narrower view of how prices might move. The Congressional Budget Office said in October 2024 that a similar plan could lower prices by more than 5 per cent. The CBO also warned the decrease could fade over time. Manufacturers could respond by changing prices or how drugs were distributed abroad.

Democrats argued any savings under the framework could be offset elsewhere. They said drugs outside the most favoured nation framework could become more expensive. Another critique focused on company profits during the policy push. In April, staff for Sen. Bernie Sanders, I-Vt., reported that 15 participating companies saw profits rise 66 per cent to USD 177 billion.

The Sanders staff report also linked the issue to earlier tax policy. It said tax cuts Trump signed last year exempted or delayed many expensive drugs from Medicare price negotiations. The Trump administration rejected that critique as flawed. Officials said the analysis used list prices rather than what patients actually paid, and said that distorted the picture.

The White House estimates placed drug prices at the centre of the midterm debate on living costs. Democrats continued to press for public disclosure and challenged whether projected savings matched real-world prices. With limited public detail on the 17 company deals, the savings numbers remained hard to verify independently, even as the administration promoted the policy’s impact.

With inputs from PTI